MolMed is now part of AGC Biologics

Learn more

AGC Biologics


AGC Inc. announces the launch of a voluntary tender offer over all ordinary shares of MolMed S.p.A. March 17, 2020 - 10:27 Sabato 15/2 Riccardo Palmisano ospite alla trasmissione TV "TGR Officina Italia", in onda su RAI3 alle 11.30 February 14, 2020 - 10:01 WSI Wall street Italia - MOLMED, LA NUOVA SFIDA DEL BIOTECH ITALIA\O January 16, 2020 - 09:19 Q&A with Riccardo Palmisano, MolMed CEO, and Finanzaonline's forum members November 19, 2019 - 12:44

GMP Solutions

Tailor made GMP services for viral vector manufacturing and cell engineering.


Novel autologous and allogeneic therapies in pre-clinical and clinical stage for the treatament of cancer

Stock information

Discover More


Video intervista a Riccardo Palmisano, CEO di MolMed, che risponde agli utenti di Finanzaonline

8 AGOSTO 2019, MolMed ospite di SuperQuark, che dedica un servizio al biotech italiano nell’ambito dei CAR T

MolMed Company presentation at MESA 2019*

* Please note: this Company presentation has been made before Zalmoxis' CMA withdrawal on October 10th, 2019

All videos

Subscribe to press releases

By subscribing to this newsletter, you confirm that you have read the Privacy Policy and agree to receive MolMed's press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the
The contents present on this portal ( are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations. 
In addition, the "work with us" section is still active, while the contact details are no longer accessible.